Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: 2018 Arctic 0.2-3 um eukaryotic 18S

PROVIDER: PRJNA674418 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12981654_1.fastq.gz	Fastqsanger.gz
	SRR12981654_2.fastq.gz	Fastqsanger.gz
	SRR12981655_1.fastq.gz	Fastqsanger.gz
	SRR12981655_2.fastq.gz	Fastqsanger.gz
	SRR12981656_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 46

Similar Datasets

Project description:2018 Arctic 3-144 um eukaryotic 18S

| PRJNA674408 | ENA

Project description:2018 Arctic 0.2-3 um Imitervirales polB

| PRJNA674422 | ENA

LMO J.Pinhassi_19_01

Project description:LMO 2018 (0.2, 3-0.2, 3)

| PRJEB52837 | ENA

water microbes

Project description:Water sample filtered through 3 um and 0.2 um

| PRJEB25897 | ENA

eukaryotic aquatic metagenome

Project description:Eukaryotic 18S metabarcoding

| PRJDB15289 | ENA

Project description:Metaranscriptomes of the Lake Baikal (fraction 0.2-5 um)

| PRJNA1043873 | ENA

Comparative toxicogenomic response in developing zebrafish to the flame retardant, mono-substituted isopropylated triaryl phosphate

Project description:mITP-induced transcriptional changes were measured in 48 hpf wild-type or ahr2hu3335 embryos exposed to 0 or 0.2 uM mITP from 6-48 hpf.

2016-12-24 | GSE86834 | GEO

bulk sample

Project description:Arctic BIOSCAN 2018-2023

| PRJNA1022048 | ENA

Gene expression profiles of Herceptin-resistant breast cancer cells

Project description:Herceptin (trastuzumab) is a humanized monoclonal antibody targeted to the Her2 receptor tyrosine kinase. Despite a robust response rate to Herceptin-based therapies in Her2-positive patients, resistance frequently arises within one year of the initial response. To address the mechanism of Herceptin resistance, we selected clonal variants of Her2-positive BT474 human breast cancer cells (BT/HerR) that are highly resistant to the anti-proliferative effects of Herceptin in the presence of 0.2 uM or 1.0 uM Herceptin. Our original report on these cell lines demonstrated sustained PI3K/Akt signaling and sensitivity to PI3K inhibitors in BT/HerR cells in the presence of Herceptin, suggesting dysregulation of that pathway as an essential component of Herceptin-resistant proliferation. To address the mechanism by which BT/HerR cells and their PI3K/Akt signaling pathway became resistant to Herceptin, we analyzed gene expression profiles of two clones (BT/HerR1.0C and BT/HerR 1.0E) that were selected in 1.0 uM Herceptin and two clones (BT/HerR0.2D and BT/HerR 0.2J) that were selected in 0.2 uM Herceptin, in comparison to the Herceptin sensitive BT474 parent cells.

2009-08-21 | GSE15043 | GEO

Project description:18S LUCAS eukaryotic soil biodiversity

| PRJNA985135 | ENA